Nanoligent is a Barcelona-based biotechnology firm focused on creating precision nanodrugs designed to combat cancer. Its technology centers on nanoscale drug constructs aimed at delivering anti-cancer agents directly to tumor cells while sparing healthy tissue. The company positions its platform as a next-generation therapeutic approach intended to improve treatment efficacy and reduce side effects compared with conventional chemotherapy. Nanoligent has attracted investor interest for its novel mechanism and potential to address significant unmet medical needs in oncology. To accelerate development, the company secured new capital in its latest financing round. This additional funding is intended to support continued research, preclinical development, and the progression of its drug candidates toward clinical evaluation.

Total raised

$15M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2025